Claims for Patent: 7,528,143

Summary for Patent: 7,528,143

Title:	Bi-aryl meta-pyrimidine inhibitors of kinases
Abstract:	The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
Inventor(s):	Glenn Noronha, Chi Ching Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved P. Pathak, Daniel L. Lohse, John D. Hood, Richard M. Soll
Assignee:	Impact Therapeutics Inc, Impact Biomedicines Inc
Application Number:	US11/588,638
Patent Claims:	1. A compound having the structure (A): wherein: X is selected from a group consisting of a bond, O, SO2, and CH2; Y is selected from a group consisting of a bond or NR9; or X and Y taken together is a bond; each of R1 and R2 is independently selected from a group consisting of H, C1-C6 alkyl, cycloalkyl; or R1 and R2 taken together is a bond; or R1 and R2 taken together form a moiety selected from a group consisting of (CH2)m, (CH2)r—S—(CH2)m, (CH2)r—SO—(CH2)m, (CH2)r—SO2—(CH2)m, (CH2)r—NR9—(CH2)m, and (CH2)r—O—(CH2)m; each of p, q, r, n, m is independently an integer having the value between 0 and 6, R9 is selected from a group consisting of H, C1-C6 alkyl, C1-C6 cycloalkyl, C1-C6 branched alkyl, C1-C6 aminoalkyl, and C1-C6 hydroxyalkyl; G0 is selected from a group consisting of N, O, H, and CH, G is CH or C when bonded to X; R5 methyl; wherein each of R6 and R7 is independently selected from a group consisting of C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 hydroxyalkyl or aminoalkyl, C1-C6 cycloalkyl, C1-C6 alkoxy, a halogen, CF3, OCF3, SO2H, SO2(C1-C6 alkyl), SO2-heterocycle, SO2-cycloalkyl, SO2N(C1-C6 alkyl)H, SO2N(C1-C6 alkyl)(C1-C6 alkyl), SO2NH(C1-C6 cycloalkyl), SO2NH-heterocycle, (SO2N(C1-C6 branched alkyl)H, NO2, CN, OH, CONH2, CO—(C1-C6 alkyl), COOH, COO—(C1-C6 alkyl), and NHCO—(C1-C6 alkyl), and R8 is independently selected from the group consisting of H, C1-C6 alkenyl, C1-C6 alkynyl, C1-C6 hydroxyalkyl or aminoalkyl, C1-C6 cycloalkyl, halogen, CF3, OCF3, SO2H ,SO2(C1-C6 alkyl), SO2-heterocycle, SO2-cycloalkyl, SO2N(C1-C6 alkyl)H, SO2N(C1-C6 alkyl)(C1-C6 alkyl), SO2NH(C1-C6 cycloalkyl), SO2NH-heterocycle, (SO2N(C1-C6 branched alkyl)HNO2, CN, OH, CONH2, CO—(C1-C6 alkyl), COOH, COO—(C1-C6 alkyl), and NHCO—(C1-C6 alkyl); A is selected from a group consisting of NH, and N—(C1-C6 alkyl); G1 is CH; G2 is CR7, with each group R7 independent of every other group R7; and R3 and R4, taken together form a heterocyclic ring system, or a pharmaceutically acceptable salt thereof. 2. A compound represented by: a first moiety chemically connected to a second moiety, or a pharmaceutically acceptable salt thereof, wherein the first moiety is selected from the group consisting of: and wherein the second moiety is selected from the group consisting of: 3. The compound of claim 1, wherein the compound is 4. The compound of claim 1, wherein the compound is 5. The compound of claim 1, wherein the compound is 6. The compound of claim 1, wherein the compound is selected from the group consisting of: 7. The compound of claim 1, wherein the compound is selected from the group consisting of: 8. The compound of claim 1, wherein the compound is selected from the group consisting of: 9. The compound of claim 1, wherein the compound is selected from the group consisting of: 10. The compound of claim 1, wherein the compound is selected from the group consisting of: 11. The compound of claim 1, wherein the compound is selected from the group consisting of: 12. The compound of claim 1, wherein the compound is 13. The compound of claim 1, wherein the compound is selected from the group consisting of: 14. A compound represented by: and a pharmaceutically acceptable salt thereof. 15. The compound of claim 1, wherein the compound is 16. The compound of claim 1, wherein the compound is 17. The compound of claim 1, wherein the compound is selected from the group consisting of: 18. A compound, wherein the compound is 19. The compound of claim 1, wherein the compound is 20. A compound wherein the compound is selected from the group consisting of: 21. The compound of claim 1, wherein the compound is selected from the group consisting of: 22. The compound of claim 1, wherein the compound is selected from the group consisting of: 23. The compound of claim 1, wherein the compound is selected from the group consisting of: 24. The compound of claim 1, wherein the compound is 25. A compound wherein the compound is selected from the group consisting of: and a pharmaceutically acceptable salt thereof. 26. The compound of claim 1, wherein the compound is 27. The compound of claim 1, wherein the compound is selected from the group consisting of: 28. The compound of claim 1, wherein the compound is 29. The compound of claim 1, wherein the compound is selected from the group consisting of: 30. The compound of claim 1, wherein the compound is 31. The compound of claim 1, wherein the compound is 32. The compound of claim 1, wherein the compound is 33. The compound of claim 1, wherein the compound is 34. The compound of claim 1, wherein the compound is 35. The compound of claim 1, wherein the compound is 36. The compound of claim 1, wherein the compound is 37. The compound of claim 1, wherein X is O. 38. The compound of claim 1, wherein G0 is N. 39. The compound of claim 37, wherein G0 is N. 40. The compound of claim 39, wherein Y is a bond, and R1 and R2 are each H. 41. The compound of claim 40, wherein R7 is SO2NH—(C1-C6 branched alkyl). 42. The compound of claim 39, wherein G2 is CH, R8 is H and R5 is H. 43. A compound represented by: or a pharmaceutically acceptable salt thereof. 44. A pharmaceutical composition comprising: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.